CJC-1295 and ipamorelin are almost always discussed together, because they are designed to be run together. It is the classic growth-hormone-support pairing, used for recovery, body composition, and the general "raise my own GH" goal rather than for direct fat loss. The logic behind combining them is genuinely sound, two different mechanisms that push the same outcome, but the human evidence is thinner than the popularity suggests. Here is the honest full breakdown.

What are CJC-1295 and ipamorelin?

Both are growth-hormone-releasing peptides, but they work through different doors. CJC-1295 is a GHRH analog, it mimics growth-hormone-releasing hormone and tells the pituitary to produce more GH. Ipamorelin is a growth hormone secretagogue (a ghrelin mimetic) that triggers GH release through a separate receptor pathway, and it is known for being selective, prompting GH release without the cortisol or prolactin elevation that some older secretagogues caused. Run together, they stimulate GH from two angles at once, which is the entire rationale for the stack.

How it works

The combination is built around synergy. CJC-1295 increases the amount of GH the pituitary is prompted to release (the GHRH side), while ipamorelin amplifies the pulse and adds a second trigger (the secretagogue side). Together they support a stronger, more natural pulsatile release of the body's own growth hormone, which then raises IGF-1. The key framing is that this is not synthetic GH; it stimulates the body's own production in pulses rather than introducing growth hormone directly. The downstream goals people pursue with it, lean-mass support, recovery, and slow improvements in body composition, all flow from that GH and IGF-1 increase.

The evidence

Here is the honest part. CJC-1295 has human data showing it raises GH and IGF-1, so the core mechanism is real and measurable. What is missing is dedicated, high-quality human trials demonstrating the downstream outcomes people actually want, meaningful fat loss, muscle gain, or recovery benefit, under the typical "clinic peptide" protocols. The recovery and body-composition benefits are largely inferred from how the GH/IGF-1 axis works rather than directly proven in controlled trials for these peptides at these doses. So the accurate read is: the GH-raising effect is established, the practical performance benefits are reasonable extrapolations from physiology rather than settled trial results. That is a meaningful distinction to keep, especially since these are often marketed as if the outcomes were proven.

Dosing (research reference)

The combination is dosed as a blend or as two co-administered peptides, and the reference ranges are consistent across sources. The typical research range is 100 to 300 mcg of each peptide once daily by subcutaneous injection, titrated gradually, usually taken before bed to align with the body's natural nighttime GH pulse.

A common titration pattern starts around 100 mcg of each peptide daily and increases by roughly 50 mcg every one to two weeks as tolerated, working toward a 200 to 300 mcg target of each over the cycle. For a reconstitution reference, a 10 mg blend (5 mg of each peptide) reconstituted with about 3 mL of bacteriostatic water gives roughly 3.33 mg/mL total (about 1.67 mg/mL per peptide), where 1 unit on a U-100 syringe is about 33 mcg of each. Reference cycles run 8 to 12 weeks, sometimes extended to 16.

Timeline

This is a slow, cumulative tool rather than a fast one. Because the effects run through raising the body's own GH and IGF-1 gradually, the changes people are after build over weeks to months of consistent nightly dosing, which is why the reference cycles are measured in months, not weeks.

Side effects

The combination is generally described as mild on side effects in the available research and reports. The most common issues are local injection-site reactions (redness, irritation) and the GH-related effects you would expect from raising growth hormone: some water retention, occasional head or joint discomfort. Ipamorelin's selectivity is part of its appeal here, since it is associated with fewer of the off-target hormonal effects (like cortisol elevation) seen with some older secretagogues. As with any GH-axis compound, the longer-term picture is less well characterized than the short-term tolerability.

Storage

Lyophilized blend is typically frozen for longer storage; once reconstituted with bacteriostatic water it is refrigerated at 2 to 8 degrees C and used within roughly 28 days, avoiding freeze-thaw cycles. Letting a vial reach room temperature before opening reduces condensation.

Where it fits

CJC-1295 plus ipamorelin is the GH-support pairing, best understood as a recovery, lean-mass-support, and recomposition tool rather than a direct fat-loss driver, since there is no weight-loss trial behind it for that purpose. It fits the person who wants to nudge their own GH and IGF-1 up in natural pulses, often alongside other goals, and who understands that the headline benefits are inferred from GH physiology more than proven in dedicated trials. Held to that honest framing, mechanism real, outcomes extrapolated, it is a reasonable GH-axis option rather than a guaranteed result.